Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects

NCT06635226

Status	RECRUITING
Phase	Phase 1
Sponsor	IlDong Pharmaceutical Co Ltd
Enrollment	36 participants

Key Eligibility Criteria

Inclusion (4)

- Healthy subjects aged 19 to 50 years at the time of Screening.
- Body mass index (BMI) within e27 kg/m2; and a total body weight e 50 kg
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
- For female subjects, not pregnant or lactation women, or naturally menopausal (spontaneous amenorrhea for at least 12 months) or surgically infertility (bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy etc).

Exclusion (3)

- Evidence or history of clinically significant hepatic, renal, neurological, immunological, pulmonary, gastrointestinal (including pancreatitis), endocrine, hematological, cardiovascular, urinary, psychiatric disease, sexual dysfunction or drug allergies.
- Treatment with an investigational drug (including a bioequivalence study) within 180 days prior to the scheduled date of first administration of the investigational product.
- Fertile male subjects who are unwilling or unable to use a highly effective method of contraception for the duration of the study and for at least 90 days after the last dose.

Locations (1 total)

Seoul National University Hospital, Seoul, South Korea